platforms, as well as to deliver therapeutics in a highly specific manner. Genisphere has successfully out-licensed several reagent kits to the research market, and provides customized products to improve the limit of detection of high-sensitivity lateral flow point-of-care tests, enabling their commercialization. Genisphere's diagnostic partners have a competitive advantage due to 3DNA’s ability to improve their test’s sensitivity, with minimal additional costs and no alterations to end user protocols. For targeted therapeutics, Genisphere provides a fully customizable all-DNA drug delivery platform. Genisphere's robust nanocarrier delivers small drug, RNAi and gene construct therapeutics with greatly improved efficacy and reduced toxicity. The company is continuing to seek partnerships with biotechnology and pharmaceutical companies that could benefit from Genisphere's platform technology.